| Detailed information |
|---|
| CancerLivER ID | 2522 |
| Biomarker | BIC, CPNE1, RBPMS, RFC4, RPSA, TOP2A |
| Biomarker Name/Symbol (given in Publication) | BIC, CPNE1, RBPMS, RFC4, RPSA, TOP2A |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Markers to distinguish diffrenetiated and dedifferentiated HCC; but not validated on independent dataset |
| Experimental Condition | moderately and well differentiated HCC v/s low-differentiated HCC |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in dedifferentiated HCC (with fold change > 2.6) |
| Level of significance | FDR < 2%. |
| Source | Tissue |
| PMID | 18820673 |
| Type of Biomarker | Diagnostic |
| Pathway | cell-cycle control and proliferation. |
| Cohort | 23 HCC patients: 4 well, 11 moderately, and 8 poorly differentiated HCC |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | moderately and well differentiated HCC v/s low-differentiated HCC |
| Year of Publication | 2008 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |